Anne Mette Dybro

Anne Mette Dybro

Auto-generated profile, based on publicly available information

Anne Mette Dybro

Aarhus University Hospital

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in JACC
Verified
Journal Article
Closed access
ADAnne M. Dybro
Anne M. Dybro
TRTorsten B. Rasmussen
Torsten B. Rasmussen
RNRoni R. Nielsen
Roni R. Nielsen
MAMads J. Andersen
Mads J. Andersen
MJMorten K. Jensen
Morten K. Jensen
SPSteen H. Poulsen
Steen H. Poulsen

1 April 2020 in International Journal of Cardiology
Verified
Journal Article
Closed access
BLBertil Ladefoged
Bertil Ladefoged
ADAnne Dybro
Anne Dybro
JPJonas Agerlund Povlsen
Jonas Agerlund Povlsen
HVHenrik Vase
Henrik Vase
TCTor Skibsted Clemmensen
Tor Skibsted Clemmensen
SPSteen Hvitfeldt Poulsen
Steen Hvitfeldt Poulsen

1 October 2023 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Open access
DCDouglas E. Cannie
Douglas E. Cannie
APAlexandros Protonotarios
Alexandros Protonotarios
ABAthanasios Bakalakos
Athanasios Bakalakos
PSPetros Syrris
Petros Syrris
MLMassimiliano Lorenzini
Massimiliano Lorenzini
Perry ElliottPerry Elliott
Perry Elliott
BACKGROUND: Variants in RBM20 are reported in 2% to 6% of familial cases of dilated cardiomyopathy and may be associated with fatal ventricular arrhythmia and rapid heart failure progression. We sought to determine the risk of adverse events in RBM20 variant carriers and the impact of sex on outcomes. METHODS: Consecutive probands and relatives carrying RBM20 variants were retrospectively recruited from 12 cardiomyopathy units. The primary end point was a composite of malignant ventricular arrhythmia (MVA) and end-stage heart failure (ESHF). MVA and ESHF end points were also analyzed separately and men and women compared. Left ventricular ejection fraction (LVEF) contemporary to MVA was examined. RBM20 variant carriers with left ventricular systolic dysfunction ( RBM20 LVSD ) were compared with variant-elusive patients with idiopathic left ventricular systolic dysfunction. RESULTS: Longitudinal follow-up data were available for 143 RBM20 variant carriers (71 men; median age, 35.5 years); 7 of 143 had an MVA event at baseline. Thirty of 136 without baseline MVA (22.0%) reached the primary end point, and 16 of 136 (11.8%) had new MVA with no significant difference between men and women (log-rank P =0.07 and P =0.98, respectively). Twenty of 143 (14.0%) developed ESHF (17 men and 3 women; log-rank P 35%. At 5 years, 15 of 67 (22.4%) RBM20 LVSD versus 7 of 197 (3.6%) patients with idiopathic left ventricular systolic dysfunction had reached the primary end point (log-rank P <0.001). RBM20 variant carriage conferred a 6.0-fold increase in risk of the primary end point. CONCLUSIONS: RBM20 variants are associated with a high risk of MVA and ESHF compared with idiopathic left ventricular systolic dysfunction. The risk of MVA in male and female RBM20 variant carriers is similar, but male sex is strongly associated with ESHF.

7 September 2016 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
ADAnne Mette Dybro
Anne Mette Dybro
PDPer Damkier
Per Damkier
TRTorsten Bloch Rasmussen
Torsten Bloch Rasmussen
MHMaja Hellfritzsch
Maja Hellfritzsch
A 47-year-old woman had been treated with high-dose simvastatin for several years. After systemic treatment with the antifungal agent itraconazole, she developed muscle pain and highly elevated levels of creatine kinase and myoglobin. Muscle biopsy was compatible with statin-associated rhabdomyolysis, probably caused by a drug–drug interaction between simvastatin and itraconazole. The patient made full recovery. Three commonly used statins—simvastatin, atorvastatin and lovastatin—are metabolised by the liver enzyme CYP3A4. Several potent inhibitors of this enzyme are known, for example, azole antifungal agents such as itraconazole and posaconazole. If antifungal treatment is indicated in a patient using a CYP3A4-metabolised statin, we recommend (1) topical administration of the antifungal agent if possible, (2) the use of a non-CYP3A4-inhibiting antifungal drug such as terbinafine or (3) temporary discontinuation of statin treatment.

11 August 2025 in European Heart Journal
Verified
Journal Article
Open access
RJRenee Johnson
Renee Johnson
RFRobert A Fletcher
Robert A Fletcher
SPStacey Peters
Stacey Peters
MOMonique Ohanian
Monique Ohanian
MSMagdalena Soka
Magdalena Soka
DFDiane Fatkin
Diane Fatkin
Background and Aims: Truncating variants in the TTN gene (TTNtv) are the most common genetic cause of dilated cardiomyopathy (DCM) but also occur as incidental findings in the general population. This study investigated factors associated with the clinical manifestation of TTNtv. Methods: An international multicentre retrospective observational study was performed in families with TTNtv-related DCM. Shared frailty models were used to estimate associations of variant characteristics with lifetime risk of DCM, and logistic regression to estimate odds ratios (ORs) for individual-level clinical risk factor profiles (cardiac conditions, cardiovascular comorbidities, lifestyle) and DCM. Results: A total of 3158 subjects in 1043 families with TTNtv-related DCM were studied. TTNtv-positive subjects were 21-fold more likely to develop DCM [OR, 21.21; 95% confidence interval (CI), 14.80–30.39]. Disease onset was earlier in males, but was similar for TTNtv of different types and locations. The presence of clinical risk factors was associated with earlier DCM onset (OR, 3.41; 95% CI, 2.06–5.64), with a prior history of atrial fibrillation having a two-fold increased odds of DCM (OR, 2.05; 95% CI, 1.27–3.32). The prevalence of clinical risk factors increased with age; however, the strength of the DCM association was greatest for young-onset (<30 years) disease (OR, 4.75; 95% CI, 2.35–9.60). Administration of beta-adrenergic receptor or renin-angiotensin system-blocking drugs prior to overt DCM was associated with 87% reduced odds of DCM (OR, .13; 95% CI, .08–.23). Conclusions: Disease onset in TTNtv-associated familial DCM is dependent on individual patient context and is potentially modifiable by risk factor management and prophylactic therapeutic intervention.

19 September 2022 in Journal of the American Society of Echocardiography
Verified
Journal Article
Closed access
ADAnne M. Dybro
Anne M. Dybro
TRTorsten B. Rasmussen
Torsten B. Rasmussen
RNRoni R. Nielsen
Roni R. Nielsen
APAnders L.D. Pedersen
Anders L.D. Pedersen
MAMads J. Andersen
Mads J. Andersen
SPSteen H. Poulsen
Steen H. Poulsen